Company says lawsuit over opioid treatment drug has no merit
The Associated Press | 09.23.16
Photo by AP Photo/M. Spencer Green
In this March 2013 photo, Shavonne Bullock, a recovering heroin addict, holds a demonstration dose of the medication Suboxone during an appointment at the West Division Family Health Center in Chicago. Each dose is incorporated on a dissolvable film, which is placed below the tongue where is dissolves and is absorbed into the bloodstream. Suboxone helps suppress withdrawal symptoms and reduce cravings for people recovering from addiction to opioid drugs.
(San Francisco) -- One of the companies alleged to have conspired to keep generic versions of a popular opioid treatment off the market says the antitrust lawsuit has no merit.
Attorneys general for 35 states filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania on Thursday, alleging that British drugmaker Indivior and New Jersey's MonoSol Rx conspired to corner the market on Suboxone.
The drug is used to treat people hooked on heroin and other painkillers.
MonoSol Rx chief executive Keith Kendall said in a statement Friday that the product has saved countless lives.
The complaint alleges the two companies conspired to make an oral strip form of the drug that they then marketed as safer than tablets, squashing competition.
Indivior has not responded to requests for comment.
Published in PA Policy